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Introduction: It is generally agreed that operative intervention is beneﬁcial in carefully selected groups of
patients with metastatic spinal cord compression (MSCC). Tokuhashi et al have presented a preoperative
scoring system to predict patient survival, which is widely used as a guideline for making a decision on
whether to operate or not. However, only limited data are available regarding the validity of the Toku-
hashi score in Southern Chinese populations.
Materials and methods: We report a series of 128 patients treated in our hospital from 2000 to 2010. All
patients were diagnosed to have spinal metastasis of different origins with cord compression. Of the 128,
59 underwent operation and the remaining 69 received conservative treatments. The Tokuhashi score
was then calculated retrospectively. The survival rate was analysed and p < 0.05 was considered sta-
tistically signiﬁcant.
Results: In our series, the accuracy of the modiﬁed Tokuhashi scoring for predicting the survival rate in
patients with MSCC was demonstrated to be 79% (101/128). The poor prognostic group showed statis-
tically signiﬁcant worse survival than the two better prognostic groups. The type of primary cancer
(p ¼ 0.0015), visceral metastasis (p ¼ 0.006), and the general condition (p < 0.001) were conﬁrmed as
signiﬁcant survival prognostic factors. Nasopharyngeal carcinoma (NPC) had the most favourable
outcome with a mean survival of 20.1 months.
Conclusion: The modiﬁed Tokuhashi score was statistically correlated to the overall survival of MSCC
patients in a Southern Chinese population. The type of primary cancer, visceral metastasis, and the
general condition were statistically signiﬁcant survival factors. We recommend weighting a higher
score for NPC in the modiﬁed Tokuhashi scoring system in view of its favourable prognosis.
中 文 摘 要
目的: 脊柱手術對於部份惡性脊柱轉移瘤造成脊髓壓迫症的患者是有成效的。德橋醫生(Tokuhashi)提出了一
個術前評分系統來預測病人的生存率，並於臨床廣泛應用以決定是否進行手術。然而，改良的德橋評
分(modiﬁed Tokuhashi score)系統對於中國南方人是否有效，仍然缺乏數據支持。
方法: 由2000至2010年間，我們對128名於本院治療的患者進行研究。所有患者均診斷為惡性脊柱轉移瘤脊
髓壓迫症。其中59人進行手術冶療，其餘69人則給予保守治療。利用改良的德橋評分作回顧性分析其存活率
並設定p值<0.05為有統計學有意義。
結果: 79﹪的病人能透過改良的德橋評分準確地預測生存期。預後為不良的組別之生存率相對於其他兩個預後
為較好的組別明顯較差。原發腫瘤的類型(p¼0.0015)，內臟轉移(p¼0.006)和身体狀況(p<0.001)被確認為重
要的生存預測因素。鼻咽癌的存活率最佳，平均生存期為20.1個月。.com.
ngOrthopaedicAssociation andHongKongCollegeofOrthopaedicSurgeons. PublishedbyElsevier (Singapore) Pte Ltd.All rights reserved.
Y.-N. Yeung et al. / Journal of Orthopaedics, Trauma and Rehabilitation 18 (2014) 15e2116討論及結論: 改良的德橋評分能準確地預測惡性脊柱轉移瘤脊髓壓迫症患者的生存期。原發腫瘤的類型，內
臟轉移和身体狀況為重要的生存預測因素。我們並建議給予鼻咽癌的惡性脊柱轉移瘤脊髓壓迫症的患者更高
的分數以表達其較佳存活率。Introduction
Metastatic spinal cord compression (MSCC) is still a challenging
problem for spine surgeons. It is a common complication secondary
to spinal metastasis and can present as a neurological emergency.
Clinical symptoms range from severe pain to neurological deﬁcit
and can adversely affect patients’ quality of life. It has been agreed
that operative intervention is beneﬁcial in some selected groups of
patients who have malignant MSCC.1e3 The aims of palliative sur-
gery are to provide symptomatic relief and restore stability as well
as function without causing further morbidity. The prognosis and
survival of the patients are still the most important considerations
for surgery. So far, various scoring systems have been developed to
predict the survival of patients to guide the treatment strategy.1e3
Tokuhashi et al presented a preoperative scoring system to
predict the survival rate in patients with spinal metastasis in 1990.1
The scoring consists of six parameters including general condition,
number of extraspinal bony metastases, number of vertebral me-
tastases, number of visceral metastases, primary site of cancer, and
spinal cord palsy. Tokuhashi et al revised the system for diverse
tumours types in 2005.2 This scoring system categorises patients
into three prognostic groups. It suggests that operation is beneﬁcial
for patients with a predicted survival beyond 6months. This system
had been shown to give a predicted value of up to 84%2 and was
widely accepted as the guideline for treatment of spinal metastasis.
Others reported predicted values in the range of 60e79%.4e10 To our
knowledge, only limited studies are available regarding the pre-
dictive value of the Tokuhashi scoring system in a Southern Chinese
population. The purpose of our study was to evaluate the predictive
value and usefulness of the Tokuhashi scoring system in a Southern
Chinese population.Materials and methods
A total of 144 patients who developed spinal metastases with
spinal cord compression were recruited retrospectively from 2001
to 2011 in our hospital.
Of these 144, 73 had spinal operative treatment for cord
compression; of these 73 patients, 13 were excluded because of
uncertain diagnosis of malignancy, no deﬁnite radiological evi-
dence of cord compression, or cord compression due to haemato-
logical malignancy. One patient was excluded because of an
inadequate follow-up period of less than 12 months.
Data from 71 patients treated conservatively were collected for
the study. All the cases were recruited in 2010 in view of
completeness of data. Most of them received radiotherapy and
steroids. Two patients were excluded because of diagnosis of hae-
matological malignancy.
Finally, 128 patients were retained for analysis; 59 of them had
surgical treatment of MSCC while 69 patients received conser-
vative therapy. The patients were followed up for 12 months at
least, if alive. The modiﬁed Tokuhashi score2 was calculated ac-
cording to the patient’s data stated in the preoperative period,
and all the parameters were analysed at the time of diagnosis of
malignant MSCC. The date of magnetic resonance imaging was
considered as the date of diagnosis and death or the date of last
study follow-up assessment (July 25, 2012) was considered as the
end point.All patients suspected to have malignant spinal cord compres-
sion were staged with a standardised diagnostic work-up by on-
cologists and orthopaedic surgeons and/or a specialised physician.
The diagnosis of malignant MSCC was conﬁrmed with either
magnetic resonance imaging and/or contrast computed tomogra-
phy. Clinical examination, abdominal ultrasound, plain radio-
graphs, computed tomography, and bone scan were used to search
for metastasis in other sites. Positron emission tomography was
also used to determine the presence of the primary tumour and
metastasis in some cases.
Our indication for surgery was a pathological fracture with
neurological compression. Excision of spinal metastasis was per-
formed only in highly selected patients with a single spinal meta-
static lesion. Decompression and instrumentation were performed
to achieve spinal stability and relieve neurological compromise.
Chemotherapy, radiotherapy, immunotherapy, hormonal therapy,
and/or local irradiation of the spinal metastasis were included as
part of the treatment according to the oncologists’ recommenda-
tions in both operated and conservative treatment groups.
Statistical analysis was carried out using IBM SPSS (International
Business Machines Corporation Statistical Package for the Social
Sciences, version 20). The ManneWhitney U test was used for
continuous variables, whereas the Chi square test or Fisher exact
test was used for categorical variables. Survival data were analysed
using KaplaneMeier survival curves. Comparisons of the survival
data of the three prognostic groups proposed by Tokuhashi et al
were performed with the log-rank test and Cox proportional haz-
ards model. Various parameters were analysed by the Cox pro-
portional hazards model for univariate and multivariate analyses.
All p values were studied by a two-tailed test, and p < 0.05 was
considered statistically signiﬁcant.
Results
Demographic data
There were 91 males and 37 females in this study. The mean age
at the time of diagnosis was 60.2 years. Standard deviation (SD) was
12.0, range was 28e90, and median was 59. At the end-point
assessment, 123 patients had died and ﬁve were alive. The preva-
lent sites of primary cancer were lung (29.7%), breast (14.8%),
prostate (9.4%), liver (7.8%), and nasopharynx (7.8%; Figure 1).
Themost frequent site of spinalmetastasiswas the thoracic spine
(46.1%), followed by the lumbosacral (15.7%) and cervical (7.8%) re-
gions; 16.4% patients had metastases involving two regions and
14.1% patients had metastases in more than two regions (Figure 2).
There was no statistically signiﬁcant difference between the
operative group and the conservative group in age, sex, site of
primary carcinoma, and sites of metastatic lesion (p ¼ 0.096;
Table 1).
The mean survival of all patients was 7.6 months (SD ¼ 14.3;
range from 5 days to 121.9 months; median ¼ 3.1 months). An
evaluation of the modiﬁed Tokuhashi score is shown in Table 2.
Operative group
There were 38 males and 21 females. The mean age at the time
of diagnosis was 58.6 years (SD ¼ 10.9; range ¼ 28e83;
Table 1
Clinical features of the 128 patients with metastatic spinal cord compression
Operation Conservative Total p
Sex Male 38 53 91 0.171
Female 21 16 37
Age Mean (SD) 58.6 (10.9) 61.3 (12.9) d 0.155
Sites of spinal
metastases
Cervical 6 4 10 0.669
Thoracic 28 31 59
Lumbar 9 9 18
Sacral 0 2 2
Two level 8 13 21
More than
two levels
8 10 18
SD ¼ standard deviation.
Figure 1. Prevalence of primary cancers of spinal metastasis with cord compression.
NPC ¼ nasopharyngeal carcinoma.
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range from 7 days to 121.9 months; median ¼ 5.3 months). The
mean modiﬁed Tokuhashi score was 8.6 (SD ¼ 2.3; range 4e14;
median¼ 8). Among all operative patients, 33 belonged to the poor
prognostic group (modiﬁed Tokuhashi score 0e8) with a median
survival of 3.1 months, 19 belonged to the moderate prognostic
group (modiﬁed Tokuhashi score 9e11) with a median survival of
9.9 months, and seven belonged to the good prognostic group
(modiﬁed Tokuhashi score 12e15) with a median survival of 12.2
months (Figure 3). The difference in survival of the three prognostic
groups was statistically signiﬁcant (p ¼ 0.030).Conservative group
There were 53 males and 16 females. The mean age at the time
of diagnosis was 61.6 years (SD ¼ 12.9; range ¼ 35e90;
median ¼ 59). The mean survival was 3.5 months (SD ¼ 5.0; range
from 5 days to 27.4 months; median ¼ 1.7 months). The mean
modiﬁed Tokuhashi score was 5.5 (SD ¼ 2.6; range: 1e13;
median¼ 5). Among all conservative patients, 59 patients belonged
to the poor prognostic group (modiﬁed Tokuhashi score 0e8) withFigure 2. The spinal regions of metastasis.a median survival of 1.4 months, nine patients belonged to the
moderate prognostic group (modiﬁed Tokuhashi score 9e11) with a
median survival of 2.1 months and one patient belonged to the
good prognostic group (modiﬁed Tokuhashi score 12e15) with a
median survival of 20.0 months. The difference in survival rate
among the three prognostic groups was statistically signiﬁcant
(p ¼ 0.029; Figure 4).
Overall survival
The meanmodiﬁed Tokuhashi score was 7.0 (SD¼ 3.0; range 1e
14; median ¼ 7). The survival data of the three prognostic groups
are shown in Table 3. The difference in survival among the three
prognostic groups was statistically signiﬁcant (p < 0.001; Figure 5).
The results of univariate and multivariate analyses of the pre-
dictors of overall survival are shown in Tables 4 and 5. In univariate
regression analysis, sex, general conditions, status of visceral
metastasis, primary type of cancer, and neurological deﬁcit affected
survival. In multivariate regression analysis, only the type of pri-
mary cancer, visceral metastasis, and the general condition were
conﬁrmed as signiﬁcant survival prognostic factors.
Although the modiﬁed Tokuhashi score is a statistically signiﬁ-
cant prognostic factor of patient’s actual survival, we can only
demonstrate signiﬁcant survival difference between the poor (0e8)
prognostic subgroup and the other two better prognostic groups.
There was no signiﬁcant survival difference between the moderate
(9e11 points) and good (12e15 points) prognostic groups (Table 6).
Discussion
Although patients with MSCC have relatively limited life ex-
pectancy, appropriate treatment can signiﬁcantly improve their
quality of life. Depending on the tumour biology, spinal metastasis
may respond favourably to different nonsurgical treatments such as
chemotherapy, radiation therapy, and hormonal therapy. However,
spine surgery should always be an option especially for patients
with profound neurological deﬁcit and spinal instability. Patchell
et al have demonstrated that there was greater improvement in
ambulatory status after decompressive spine surgery and radiation
compared with radiation alone.11 Fujibayashi et al have shown that
81% of patients were either very satisﬁed or satisﬁed with palliative
surgery with correlation to improvement of neurological status.12
However, surgical risks must be weighed against predicted life
survival to justify surgical intervention in this group of metastatic
patients. Tokuhashi et al and Tomita et al suggested a surgical
procedure for patients with predicted survival beyond 6 months.2,3
Predicted life expectancy is still the main concern before oper-
ation. Several preoperative scoring systems have been developed to
provide guidance for selection of patients as well as type and
magnitude of spinal surgery.1e3,13,14 The modiﬁed Tokuhashi
Table 2
Modiﬁed Tokuhashi scoring for survival prognosis in spinal metastasis of our patients
Parameters Score (points) No. of patients in the
operative group
No. of patients in the
conservative group
Total no. of patients
General conditions
Poor (KPS10e40) 0 1 22 23
Moderate (KPS 50e70) 1 47 40 87
Good (KPS 80e100) 2 11 7 18
No. of extraspinal bone metastases foci
3 0 13 35 48
1e2 1 8 14 22
0 2 38 20 58
No. of metastases in the vertebral bodies
>3 0 36 57 93
2 1 13 6 19
1 2 10 6 16
Metastases to the major internal organs
Unremovable 0 8 36 44
Removable 1 1 1 2
No metastases 2 50 32 82
Primary site of the cancer
Pancreas, oesophagus, stomach, bladder,
osteosarcoma, lung
0 11 33 44
Liver, gall bladder, unidentiﬁed 1 9 7 16
Others 2 16 10 26
Uterus, kidney 3 3 4 7
Rectum 4 1 0 1
Thyroid, prostate, breast, carcinoid 5 19 15 34
Spinal cord palsy (Frankel grading *)
Complete (Frankel A and B) 0 1 10 11
Incomplete (Frankel C and D) 1 46 41 87
None (Frankel E) 2 12 18 30
Tokuhashi prognostic group
Survival less than 6 mo 0e8 33 59 92
Survival more than 6 mo 9e11 19 9 28
Survival more than 12 mo 12e15 7 1 8
Summary 59 69 128
Frankel Grading: A ¼ complete neurological injury; B ¼ sensation preserved; C ¼ nonfunctional motor preserved; D ¼ functional motor preserved; E ¼ normal motor and
sensory function.
KPS ¼ Karnofsky’s performance status.
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reviewed for its accuracy. Tokuhashi et al reported the modiﬁed
scoring system with a reliability of 86.4% in 118 prospectively
evaluated patients and 82.5% in 246 retrospectively evaluated pa-
tients in 2005.2 Ulmar et al had demonstrated a reliability of 71.0%
(154/217) with the modiﬁed Tokuhashi scoring system. Ulmar et alFigure 3. Survival curve for the three prognostic groups in operative patients.
Cum ¼ cumulative.further categorised the patients into two groups, namely, survival
less than 1 year and survival beyond 1 year, which showed an even
higher reliability of the scoring up to 74.2% (161/217).4 In another
study, Ulmar et al also demonstrated the use of Tokuhashi score
with the modiﬁcation of the prognosis group and showed statisti-
cally signiﬁcant predicted survival rate in patients with breast
cancer.6 Yamashita et al reported a reliability of 79% (67/85) withFigure 4. Survival curve for the three prognostic groups in conservative patients.
Cum ¼ cumulative.
Table 3
Accuracy of the modiﬁed Tokuhashi scoring
0e8 points 9e11 points 12e15 points
N 92 28 8
Mean  SD (mo) 4.9  13.1 12.3  12.3 22.7  22.1
Median (mo) 2.2 8.7 12
Correctly estimated 77 19 5
Incorrectly estimated 15 9 3
Accuracy 83.70% 69% 63%
SD ¼ standard deviation.
Table 4
Univariate analyses by Cox regression test
p
Sex 0.004 *
Age 0.052
Level of vertebral metastasis 0.577
Revised Tokuhashi score <0.001 *
General condition (KPS) <0.001 *
Number of vertebral metastases 0.482
Number of extraspinal bone metastases 0.264
Visceral metastasis 0.001 *
KPS ¼ Karnofsky’s performance status.
* Statistically signiﬁcant.
Table 5
Multivariate analyses by Cox regression test
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mance status and existence of organ metastases signiﬁcantly
correlated with poor survival.10 Putz et al demonstrated the posi-
tive correlation of neurological improvement after surgery to the
Tokuhashi score.15 Pointillart et al showed an overall accuracy of
less than 60% with the modiﬁed Tokuhashi scoring system in a
European population.8
A total of 79% (101/128) accuracy of the modiﬁed Tokuhashi
scoring system in predicting the survival rate among patients with
MSCC was demonstrated in our series. The accuracy of the three
prognostic subgroups is 84% (77/92) in the poor prognostic group,
69% (19/28) in the moderate prognostic group, and 63% (5/8) in the
good prognostic group. The relatively small sample size in the
moderate and good prognosis groups can bias the statistical power
of this result. This limitation is also present in most of the other
studies.4,8e10 Our result showed a signiﬁcant survival difference
between the poor prognostic subgroup and the other two better
prognostic groups only. This ﬁnding was compatible with the result
of Wibmer et al and Yamashita et al7,10 in which the Tokuhashi
scoring system failed to distinguish signiﬁcantly between the good
and moderate prognostic groups.
We believed that the extent of surgery is highly individualised
and cannot just depend on the single scoring system. We agree
with Tokuhashi et al and Tomita et al that surgical treatment is
beneﬁcial if patient survival is beyond 6 months. Therefore, the
distinction between these two patient groups is utmost important
for us. This type of inaccuracy does not inﬂuence our treatment
algorithm.
The survival of spinal metastasis patient is inﬂuenced by
multiple variables including the patient and the tumour factors.
Our study showed that general conditions, primary type of cancer,
and visceral metastasis were independent survival factors in uni-
variate and multivariate survival analysis. However, the inﬂuenceFigure 5. Survival curve for the three prognostic groups in all patients.
Cum ¼ cumulative.of general condition as a prognostic factor for survival is contro-
versial.1e3,7e10,13,16 Karnofsky’s performance status (KPS)20 is used
for assessing the general condition in Tokuhashi scoring. Wibmer
et al reported that poor KPS (<40) had a better prognosis than
moderate KPS (50e70), and the author explained that KPS might
not reﬂect the general condition in spinal metastasis cases in
which the patient had to be immobilised due to cord compres-
sion.7 Tomita et al did not accept the general condition as one of
the prognostic factors, but instead suggested that the prognosis
should be predicted by aggressiveness of cancer and visceral
metastasis.3 Our result showed that general conditions in terms of
KPS show a signiﬁcant effect on patient survival. The hazard ratio
(HR) was 6.89 for poor performance status (KPS 10e40) and 2.62
for the moderate performance status (KPS 50e70) compared with
reference values. This result supports other literature reports that
noted poor functional status associated with poorer survival.8,10,13
Another controversy was the prognostic value of neurological
deﬁcit. Harrington suggested that the rapid onset of muscular
weakness had a considerable inﬂuence on the ultimate prognosis.14
Hosono et al reported that paresis was associated with poor sur-
vival.16 However, our study could not establish its signiﬁcance in
multivariate analysis. This result was compatible with other
studies.3,5,7e10,13 In accordance with Tomita et al, patients with
paralysis seem to die sooner because of progression of the cancer,
and not because of the paralysis.3 We observed that the presence of
visceral metastasis was associated with poorer survival with HRVariables Score HR p 95% CI
Sex 1.37 0.187 0.86e2.20
Neurological deﬁcit (Frankel grade) 0.623
Complete (A and B) 0 0.67 0.3471 0.26e1.54
Incomplete (C and D) 1 0.92 0.755 0.56e1.52
None (E) 2 1
General condition <0.001*
Poor: KPS 10e40 0 6.89 <0.001 3.07e15.46
Moderate: KPS 50e70 1 2.62 0.002 1.41e4.86
Good: KPS 80e100 2 1
Visceral metastasis 0.006 *
Unremovable 0 1.73 0.009 1.15e2.62
Removable 1 4.82 0.036 1.11e20.99
None 2 1
Primary cancer type 0.0015*
Lung, bladder, stomach 0 1.86 0.031 1.06e3.26
Liver, unidentiﬁed 1 2.49 0.011 1.23e5.01
Others 2 0.96 0.889 0.51e1.78
Kidney, uterus 3 2.76 0.023 1.15e6.65
Rectum 4 0.59 0.613 0.77e4.52
Breast, prostate, thyroid 5 1
CI ¼ conﬁdence interval; HR ¼ hazard ratio; KPS ¼ Karnofsky’s performance status.
* Statistically signiﬁcant.
Table 6
Cox regression analyses between the three Tokuhashi prognostic groups
Tokuhashi prognostic groups HR p 95% CI
Poor (0e8 points) versus good
(12e15 points) R
4.226 0.001 1.81e9.88
Moderate (9e11 points) versus
good (12e15 points) R
1.856 0.174 0.76e4.53
Moderate (9e11 points) versus
poor (0e8 points) R
0.439 <0.001 0.28e0.69
CI ¼ conﬁdence interval; HR ¼ hazard ratio; R ¼ reference group.
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that reported that the extent of visceral metastasis had a signiﬁcant
impact on patient survival.1e3,7,9,10,13,16
The type of primary cancer was suggested to be the main
prognostic factor affecting patient survival.1e5,7e10,13,16 Tokuhashi
et al had revised the scoring system by diversifying the different
primary cancers.2 The impact of the types of cancer has been re-
ﬂected by scoring of more points by types of tumours in the
modiﬁed scoring system. Our analysis also supported this impor-
tant prognostic factor in patient survival. Although the modiﬁed
Tokuhashi scoring system had covered most of the cancers, some
prevalent cancers in our locality such as nasopharyngeal carcinoma
(NPC) have not been properly classiﬁed. NPC is endemic in South
East Asia and Southern China. In Hong Kong, NPC is the seventh
most frequent tumour.17 Although this aggressive tumour often
presents with local inﬁltration and distant metastasis, aggressive
treatment with radiotherapy and chemotherapy can achieve a
reasonably high chance of cure and a relatively long-term survival
even in a metastatic setting. Ngan et al reported a median survival
of 15 months in metastatic or recurrent NPC patients treated with
two-drug combinational chemotherapy.18 Leong et al demon-
strated a median survival rate of 22 months in metastatic NPC
patients treated with three-drug combinational chemotherapy.19 In
our series, NPC constituted 7.8% of cases with a mean survival of
20.1 months  37.6 and a median of 7 months (Table 7). When
compared with other groups of cancer proposed by Tokuhashi, NPC
showed signiﬁcantly more favourable survival outcome. In view of
the favourable response of NPC towards systemic chemotherapy
and radiation therapy, we would recommend a higher scoring for
NPC in the modiﬁed Tokuhashi scoring system.
The advancement of radiotherapy, chemotherapy, and immu-
notherapy has signiﬁcantly improved the survival rate in different
cancers. In accordance with Wibmer et al, we believe that theTable 7
Survival related to different types of cancers
Entity of primary
cancer
N Mean survival  SD (mo) Range (mo) Median
(mo)
Thyroid 3 19.1  28.3 2.1e51.7 3.4
Breast 19 15.6  16.0 0.8e59.6 7.9
Prostate 12 7.3  8.8 0.3e27.4 3.2
Rectum 2 8.2  10.1 1.0e15.3 8.2
Renal 6 1.6  0.4 1.3e2.2 1.5
Uterus 2 5.8  4.7 2.5e9.1 5.8
NPC 10 20.1  37.6 0.2e121.8 7.0
Colon 8 5.4  7.0 0.5e18.5 1.7
Others 4 6.6  7.1 0.3e16.8 4.7
Liver 10 2.6  1.9 0.3e20.9 2.1
Unidentiﬁed 8 4.0  4.4 0.4e11.1 1.3
Lung 38 4.0  4.9 0.3e20.9 2.1
Sarcoma 1 5.6 d d
Stomach 1 0.2 d d
Bladder 3 1.2  1.1 0.5e2.5 0.6
Oesophagus 1 0.3 d d
N ¼ number of cases; NPC ¼ nasopharyngeal carcinoma; SD ¼ standard deviation.aggressiveness of the tumour as well as its sensitivity towards
systemic therapy should be considered in deﬁning the prognosis of
the patients in future.7
However, the ﬁndings of the study might be biased by patient-
selection criteria and its retrospective nature. The patient group
was heterogeneous and the number of cases was relatively small.
This might affect the statistical power of the study. A multicentre
study with a larger population is therefore suggested to better
delineate the accuracy of the modiﬁed Tokuhashi scoring system in
a Southern Chinese population. Besides, the outcome of the con-
servative treatment group may be biased due to the advancement
in systemic treatment of cancer in recent years.
Conclusion
The modiﬁed Tokuhashi score was statistically correlated to the
overall survival of patients with MSCC in a Southern Chinese
population. General condition, primary type of cancer, and pres-
ence of visceral metastasis were independent predictors of overall
survival. The poor prognostic group showed signiﬁcantly worse
survival than the two better prognostic groups. The modiﬁed
Tokuhashi score was a signiﬁcant tool to distinguish patients in
the conservative group with predicted survival less than 6 months.
We recommend a higher rating for NPC in the modiﬁed scoring
system in view of its favourable prognosis. It is important that the
decision of performing an operation should not be based on a
single scoring system alone. Various factors, especially the
response of the primary tumour to systemic therapy and radio-
therapy, should be seriously considered. Therefore, a multidisci-
plinary approach with an oncologist should be advocated for every
case of MSCC.
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